Antipsychotic drugs; vendor drug program; Oklahoma Health Care Authority; prior authorized; disorders; prior authorization; effective date.

HB 2801 requires Oklahoma's Medicaid program to approve prior authorization for non-preferred atypical antipsychotic drugs when treating mood disorders, schizophrenia, or related conditions. It mandates coverage if a patient has either failed a trial of a preferred drug in the past year or is stable on a non-preferred medication. The bill ensures these medications are available at the same level as other branded drugs in their class. This directly affects Medicaid patients needing these treatments and their healthcare providers, who must submit claims or provider attestation for approval. The policy change takes effect November 1, 2025.